About Annexin A11
Annexin A11 (ANXA11) is a protein
from Homo sapiens identified by UniProt accession
P50995, 505 residues long.
MolForge cross-references it against 0 known binders and
86 disease associations.
Target properties
| Protein name | Annexin A11 |
| UniProt accession | P50995 |
| Gene | ANXA11 |
| Organism | Homo sapiens |
| Length | 505 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (86)
Diseases linked to this target (Open Targets).
- amyotrophic lateral sclerosis · score 0.65
- inclusion body myopathy and brain white matter abnormalities · score 0.46
- sarcoidosis · score 0.39
- Amyotrophic lateral sclerosis · score 0.38
- oculopharyngeal muscular dystrophy · score 0.34
- immune system disease · score 0.27
- genetic disorder · score 0.19
- serum urea measurement · score 0.14
- axial length measurement · score 0.10
- drug use measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50995-F1 | alphafold | PREDICTED | 75.79 | — |
Amino-acid sequence (505 residues)
MSYPGYPPPP GGYPPAAPGG GPWGGAAYPP PPSMPPIGLD NVATYAGQFN QDYLSGMAAN MSGTFGGANM PNLYPGAPGA GYPPVPPGGF GQPPSAQQPV PPYGMYPPPG GNPPSRMPSY PPYPGAPVPG QPMPPPGQQP PGAYPGQPPV TYPGQPPVPL PGQQQPVPSY PGYPGSGTVT PAVPPTQFGS RGTITDAPGF DPLRDAEVLR KAMKGFGTDE QAIIDCLGSR SNKQRQQILL SFKTAYGKDL IKDLKSELSG NFEKTILALM KTPVLFDIYE IKEAIKGVGT DEACLIEILA SRSNEHIREL NRAYKAEFKK TLEEAIRSDT SGHFQRLLIS LSQGNRDEST NVDMSLAQRD AQELYAAGEN RLGTDESKFN AVLCSRSRAH LVAVFNEYQR MTGRDIEKSI CREMSGDLEE GMLAVVKCLK NTPAFFAERL NKAMRGAGTK DRTLIRIMVS RSETDLLDIR SEYKRMYGKS LYHDISGDTS GDYRKILLKI CGGND
Explore Annexin A11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets